975 A phase I/II single arm trial to determine the safety, tolerability, and biological activity of intrahepatic delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers (MTC-DOX) in patients with metastatic tumors in the liver

Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles

“…At present, intra‐arterial injection of chemotherapeutic agents is approved and well accepted for treatment of liver metastases, and it has occasionally been used for other tumor types such as inoperable head and neck tumors 21. Many other studies also confirmed the efficacy of arterial administration of magnetic targeting 3, 4, 22, 23. Currently, the doxorubicin hydrochloride absorbed to magnetic targeted carriers (MTC‐DOX) is under clinical investigation for the treatment of patients with primary hepatocellular carcinoma (HCC).…”

“…It was reported that the particles could be retained at HCC under the applied magnetic field after 28 days by intraarterial administration in human clinical trials 21. Furthermore, a multicenter, phase I/II trial of hepatic intraarterial deliver of MTC‐DOX in patients with HCC and a phase I/II dose escalation study of MTC‐DOX in patients with metastatic liver tumors have been undertaken, the results indicated that MTC‐DOX could be localized regionally following intraarterial administration without clinically significant toxicities in all cases 4, 23…”

“…Concerning magnetic targeting, there are many practical applications of the magnetic nanoparticles, such as magnetic drug targeting,2–5, 20, 23, 24 magnetic fluid hyperthermia,6 and MRI 9, 19. The magnetic nanoparticles can act as carriers of drug and gene for site‐specific drug and gene delivery.…”

“…Compared with other targeting vectors, such as ligand‐targeting particulates and enzyme‐triggered drug release system, magnetic targeting system is feasible to produce, reliable to control and can be specifically modified for drug delivery applications. Current applications of magnetic targeting system include magnetic delivery of chemotherapy drugs to tumors,2–4 magnetic targeting of radioisotope,1, 5 magnetic hyperthermia,6 magnetically enhanced gene therapy,7 and magnetic embolization 8. Some successes are achieved, but the results from both laboratory and clinical trials are far from satisfactory.…”

“…If the target site is a tumor outside RES, the passive accumulation in RES becomes a significant negative factor, and this is one reason why magnetic targeting carrier is still far from satisfactory. Compared with intravenous injection, the artery injection has more advantages, since the magnetic carriers have more chances to access to the target site, avoid clearance by RES, and then stopped by external magnetic filed 2–4…”